Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Cytoplasmic immunoglobulin content in multiple myeloma.

Barlogie B, Alexanian R, Pershouse M, Smallwood L, Smith L.

J Clin Invest. 1985 Aug;76(2):765-9.

2.

Intracytoplasmic and surface-bound immunoglobulins in "nonsecretory" and Bence-Jones myeloma.

Preud'Homme JL, Hurez D, Danon F, Brouet JC, Seligmann M.

Clin Exp Immunol. 1976 Sep;25(3):428-36.

3.

Dual parameter analysis of myeloma cells by flow cytometry. DNA content of cells containing monotypic cytoplasmic immunoglobulin.

Chan CS, Wormsley SB, Peter JB, Schechter GP.

Am J Clin Pathol. 1989 Jan;91(1):12-7.

PMID:
2910012
4.

Novel type of clonally involved cytoplasmic immunoglobulin-negative cells in multiple myeloma: flow cytometric study.

Shimazaki C, Gotoh H, Oku N, Ashihara E, Inaba T, Murakami S, Ura Y, Nakagawa M, Fujita N.

Acta Haematol. 1992;88(2-3):86-91.

PMID:
1466204
5.

A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique.

Orfäo A, García-Sanz R, López-Berges MC, Belén Vidriales M, González M, Caballero MD, San Miguel JF.

Cytometry. 1994 Dec 1;17(4):332-9.

6.

DNA content analysis of peripheral blood B-lymphocytes in plasma cell malignancies.

Montecucco C, Riccardi A, Mazzini G, Danova M, Ucci G, Giordano PA.

Basic Appl Histochem. 1985;29(3):275-82.

PMID:
3877500
7.
8.

Multiple myeloma with monoclonal IgG and IgD of lambda type exhibiting, under treatment, a shift from mainly IgG to mainly IgD.

Gallart T, Bladé J, Martínez-Quesada J, Sierra J, Rozman C, Vives J.

Immunology. 1985 May;55(1):45-57.

9.

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.

Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, Bertucci F, Birnbaum D, Nguyen C, Harousseau JL, Bataille R, Houlgatte R, Minvielle S.

Blood. 2003 Jun 15;101(12):4998-5006. Epub 2003 Mar 6.

10.

Prognostic implications of tumor cell DNA and RNA content in multiple myeloma.

Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K.

Blood. 1985 Aug;66(2):338-41.

11.

Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains.

Jiwani S, Bornhost J, Alapat D.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8536-44. eCollection 2015.

13.

Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma.

Morgan RJ Jr, Gonchoroff NJ, Katzmann JA, Witzig TE, Kyle RA, Greipp PR.

Am J Hematol. 1989 Apr;30(4):195-200.

PMID:
2929579
14.

Flow cytometric DNA analysis and clinical correlations in multiple myeloma.

Tienhaara A, Pelliniemi TT.

Am J Clin Pathol. 1992 Mar;97(3):322-30.

PMID:
1543155
15.

Activity of multiple light chain genes in murine myeloma cells producing a single, functional light chain.

Alt FW, Enea V, Bothwell AL, Baltimore D.

Cell. 1980 Aug;21(1):1-12.

PMID:
6773666
17.

Pseudo-nonsecretory multiple myeloma with light chain deposition disease.

Matsuzaki H, Yoshida M, Akahoshi Y, Kuwahara K, Satou T, Takatsuki K.

Acta Haematol. 1991;85(3):164-8.

PMID:
1904181
18.

Surface immunoglobulin light chain expression in pre-B cell leukemias.

Koziner B, Stavnezer J, Al-Katib A, Gebhard D, Mittelman A, Andreeff M, Clarkson BD.

Ann N Y Acad Sci. 1986;468:211-26.

PMID:
2425686
19.

The DNA content of human plasma cells.

Brox L, Mowles D, Pollock B, Belch A.

Cancer. 1981 May 15;47(10):2433-6.

Supplemental Content

Support Center